Clinical Trial Update: Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares 3-month versus 6-month solifenacin treatment for female overactive bladder, with current status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solifenacin (solifenacin)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Overactive Bladder Syndrome | Phase 4 | Status: UNKNOWN